美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Invesco Nasdaq Biotechnology ETF

33.43

-0.8148-2.38%

盘后：33.440.0066+0.02%19:30 EDT

成交量：4.33万

成交额：145.21万

市值：1.08亿

市盈率：- -

高：34.02

开：34.02

低：33.43

收：34.25

52周最高：36.84

52周最低：25.00

股本：322.00万

流通股本：322.00万

量比：0.99

换手率：1.34%

股息：0.39

股息率：1.17%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

绿竹生物-B(02480)：重组RSV疫苗在中国获临床试验批准

绿竹生物-B：2026年重组RSV疫苗获中国临床试验批准

普莱柯：获得非洲猪瘟亚单位疫苗临床试验批件

华东医药：控股子公司注射用DR30206临床试验获批

白云山(600332.SH)子公司舒筋健腰丸获批临床试验

白云山：子公司舒筋健腰丸新增适应症获临床试验批准

万泰生物(603392.SH)：冻干重组呼吸道合胞病毒疫苗(CHO细胞)获批临床试验

LSEG：2026年前三季度中国并购交易总额2741亿美元同比下降10%

LSEG：2026年前三季度中国并购交易总额2741亿美元同比下降10%

【券商聚焦】华泰证券港股策略：油价及美债不确定性仍存继续在红利及创新药中选股

港股概念追踪 | 三季报大幕拉开！AI、创新药等领域获关注投资者应如何布局三季报行情？(附概念股)

智通财经网

国产创新药“出海”如何走远走实？

亿腾嘉和：GB268结直肠癌II期临床试验获批

精华制药(002349.SZ)：季德胜蛇药片新增带状疱疹适应症获药物临床试验批准

我武生物(300357.SZ)获得人脐带间充质干细胞II型注射液药物临床试验批准

百利天恒(688506.SH)：宜泽康®联合放疗治疗局部晚期不可切除头颈鳞癌及其他实体瘤获得药物临床试验批准

精华制药：季德胜蛇药片2026年获批带状疱疹临床试验

我武生物：获得干细胞注射液药物临床试验批准通知书

百利天恒：宜泽康联合放疗临床试验获批

清华证研院：创新药板块景气修复与医疗器械自主可控构成9月主线

东方财富网

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/IBBQ/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":33.4334,"timestamp":1791921600000,"preClose":34.2482,"halted":0,"volume":43277,"hourTrading":{"tag":"盘后","latestPrice":33.44,"preClose":33.4334,"latestTime":"19:30 EDT","volume":143,"amount":4820.2502,"timestamp":1791934204007,"change":0.0066,"changeRate":0.000197,"amplitude":0},"delay":0,"changeRate":-0.02379103135347254,"floatShares":3220001,"shares":3220001,"eps":0,"marketStatus":"已收盘","change":-0.8148,"latestTime":"10-13 16:00:00 EDT","open":34.02,"high":34.02,"low":33.4334,"amount":1452145.02082,"amplitude":0.017128,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.2482,"sharesOutstanding":2520001,"nav":34.23493,"aum":110578858.13493,"dividendRate":0.011701,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.44,"preClose":33.4334,"latestTime":"19:30 EDT","volume":143,"amount":4820.2502,"timestamp":1791934204007,"change":0.0066,"changeRate":0.000197,"amplitude":0},"volumeRatio":0.993512,"impliedVol":0.1579,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":3220001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.993512,"shares":3220001,"dividePrice":0.3912,"high":34.02,"amplitude":0.017128,"preClose":34.2482,"low":33.4334,"week52Low":25,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":33.4334,"eps":0,"divideRate":0.011701,"volume":43277,"delay":0,"ttmEps":0,"open":34.02,"prevYearClose":28.3962,"prevWeekClose":34.62,"prevMonthClose":35.14,"prevQuarterClose":35.14,"fiveDayClose":33.9,"twentyDayClose":34.25,"sixtyDayClose":32.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"IBBQ","amount":0.23037,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674573874","title":"绿竹生物-B(02480)：重组RSV疫苗在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674573874","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674573874?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:03","pubTimestamp":1791803010,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿竹生物-B(02480)发布公告，本集团开发的重组呼吸道合胞病毒(RSV)疫苗(重组RSV疫苗)已获中华人民共和国(中国)国家药品监督管理局批准，可在中国开展临床试验。该产品是本集团自主研发的预防由RSV引起的下呼吸道疾病(LRTD)的重组蛋白疫苗候选产品。其属于液体剂型含铝佐剂疫苗，采用RSV融合前F(Pre-F)蛋白抗原。本次临床试验获批为本集团后续重组蛋白疫苗候选品种的开发工作奠定了坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02480","IBBJ","PSYK","IBBQ","BK1161","MDTX","BMED","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674687435","title":"绿竹生物-B：2026年重组RSV疫苗获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674687435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674687435?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:01","pubTimestamp":1791802899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","MDTX","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674104876","title":"普莱柯：获得非洲猪瘟亚单位疫苗临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2674104876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674104876?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 17:56","pubTimestamp":1791798985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","IBBJ","MDTX","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674660875","title":"华东医药：控股子公司注射用DR30206临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2674660875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674660875?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 17:31","pubTimestamp":1791797501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","MDTX","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674820619","title":"白云山(600332.SH)子公司舒筋健腰丸获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2674820619","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674820619?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 16:11","pubTimestamp":1791792684,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)发布公告，近日，公司子公司广州白云山陈李济药厂有限公司(简称“陈李济药厂”)收到国家药品监督管理局核准签发的关于舒筋健腰丸新增功能主治的《药物临床试验批准通知书》。同意本品开展用于腰椎间盘突出症肝肾不足、风湿瘀阻证的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","PSYK","BK0012","IBBJ","BK1515","BK0096","BK1197","BK1521","BK1606","BK0070","MDTX","BK0175","600332","BK0028","IBBQ","BK0196","BK0097","00874","BK0239","BMED","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674820562","title":"白云山：子公司舒筋健腰丸新增适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674820562","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674820562?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 16:09","pubTimestamp":1791792592,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","MDTX","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674270708","title":"万泰生物(603392.SH)：冻干重组呼吸道合胞病毒疫苗(CHO细胞)获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2674270708","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674270708?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 16:01","pubTimestamp":1791792078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司万泰沧海收到国家药监局核准签发的冻干重组呼吸道合胞病毒疫苗(CHO细胞)的《药物临床试验批准通知书》。同意开展预防60岁及以上人群由呼吸道合胞病毒(RSV)感染引起的下呼吸道疾病的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK0239","603392","BK1200","LU1981816686.USD","IBBQ","IBBJ","PSYK","BMED","09633","BK1589","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674821376","title":"LSEG：2026年前三季度中国并购交易总额2741亿美元 同比下降10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674821376","media":"智通财经","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674821376?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 14:08","pubTimestamp":1791785332,"startTime":"0","endTime":"0","summary":"中国企业海外并购交易总额为179亿美元，同比增长2.2%。中国境内并购交易金额为2,359亿美元，同比下降10.6%。从行业来看，高科技行业在涉及中国的并购交易中位居首位，市场份额为24.8%，交易金额达681亿美元，同比增长69.6%。该交易为2026年前三季度中国规模最大的并购交易。在2026年前三季度“涉及中国的已公布并购交易”法律顾问排行榜中，按相关交易金额计算，君合律师事务所、嘉源律师事务所和方达律师事务所位列前三。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IYH","XLFI","RFG","AAUM","BK4585","MNA","FFSM","VXF","IBBQ","PBPH","GTPE","TBXU","ACTV","DFMC","BK4588","CANC","IEFN","MMID","PEVC","RSPH","UYG","TMED","PRVT","PSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674821370","title":"LSEG：2026年前三季度中国并购交易总额2741亿美元 同比下降10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674821370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674821370?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 14:08","pubTimestamp":1791785332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSP","MMID","PRVT","RFG","BK4585","IBBQ","RSPH","TBXU","PEVC","XLFI","AAUM","IYH","MNA","DFMC","TMED","UYG","BK4588","VXF","FFSM","GTPE","CANC","IEFN","ACTV","PBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674884271","title":"【券商聚焦】华泰证券港股策略：油价及美债不确定性仍存 继续在红利及创新药中选股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674884271","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674884271?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 08:48","pubTimestamp":1791766127,"startTime":"0","endTime":"0","summary":"配置上，油价及美债收益率仍是约束港股风险偏好和估值修复空间的主要矛盾。创新药及CXO龙头仍是景气占优且中美共振的进攻方向，可继续持有，重点在选股并做好止盈。饮料乳品等必需消费仍缺催化，保持耐心。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993422","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UBmain","ZROZ","IBBQ","PXJ","VDE","DUG","VXUS","IEF","MTNmain","BOXX","USHY","DRLL","TLH","MUB","TMF","ZBmain","IEI","JPST","DIG","MWNmain","XBIL","DRIP","XES","KCAI","WEEI","ZNmain","CIVG","EIM","BND","ZFmain","MEDX","EDV","601688","DBO","ZTmain","IXC","TLT","USE","SHV","LNGR","TNmain","MINT","VCSH","DBC","GBIL","SHY","OILK","SPXT","GOVT","SGOV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674417038","title":"港股概念追踪 | 三季报大幕拉开！AI、创新药等领域获关注 投资者应如何布局三季报行情？(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674417038","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674417038?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 07:06","pubTimestamp":1791759963,"startTime":"0","endTime":"0","summary":"从研报角度看，机构普遍看好三季报绩优股表现。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20261012/20261012070628_23221.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20261012/20261012070628_23221.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["KCAI","BK4588","AIPO","QTOC","MEDX","159992","06978","BK4585","ARTY","VTHR","BK1574","IBBQ","BK1161","CHAT","LNGR","AGIX","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674848723","title":"国产创新药“出海”如何走远走实？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674848723","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674848723?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 23:15","pubTimestamp":1791731700,"startTime":"0","endTime":"0","summary":"■张敏今年以来，国产创新药全球化进程持续向前，多项海外授权交易落地，行业也在全球临床与注册实践中接受检验、迭代成长。一方面，国产创新药持续通过License-out（对外授权）模式叩开国际市场大门。今年以来，我国创新药对外授权交易总额已突破1200亿美元。另一方面，国产创新药在海外临床开发、药品注册等环节，持续迎来考验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610113892128710.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610113892128710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1161","BK1574","MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674881734","title":"亿腾嘉和：GB268结直肠癌II期临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2674881734","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674881734?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 18:41","pubTimestamp":1791715260,"startTime":"0","endTime":"0","summary":"10月11日，亿腾嘉和（06998）发布公告，宣布其高度差异化创新的PD-1/CTLA-4/VEGF三特异性抗体GB268联合化疗在晚期结直肠癌的II期临床试验申请已于2026年10月9日获得中国国家药品监督管理局批准。这一进展标志着GB268的临床开发方案获得监管机构初步认可，为公司的后续推进奠定了坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610113892081935.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610113892081935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MDTX","BK1161","BK1583","BK1574","BMED","PSYK","IBBQ","IBBJ","06998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674481233","title":"精华制药(002349.SZ)：季德胜蛇药片新增带状疱疹适应症获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674481233","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674481233?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 17:04","pubTimestamp":1791709463,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精华制药(002349.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》(受理号：CXZL2600062;通知书编号： 2026LP03037)，公司季德胜蛇药片增加功能主治用于带状疱疹(肝胆湿热证)的临床试验申请获得批准。季德胜蛇药片为公司现有已上市品种，本次获批事项系已上市中药品种增加功能主治的临床试验申请获得批准，不会对公司当期经营业绩产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK0239","IBBJ","PSYK","MDTX","002349","BK0102","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674812840","title":"我武生物(300357.SZ)获得人脐带间充质干细胞II型注射液药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674812840","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674812840?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 17:02","pubTimestamp":1791709345,"startTime":"0","endTime":"0","summary":"截至本公告披露日，国内外尚未有治疗脓毒症和脓毒性休克的间充质干细胞药物获批上市。脓毒症是感染引起宿主反应失调，导致危及生命的器官功能损害的高病死率的临床综合征。脓毒性休克为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较单纯脓毒症更高。目前，针对脓毒症和脓毒性休克的治疗策略主要局限于支持性治疗与广谱抗菌药物的应用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300357","BK0028","MDTX","BMED","IBBJ","PSYK","BK0239","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674814449","title":"百利天恒(688506.SH)：宜泽康®联合放疗治疗局部晚期不可切除头颈鳞癌及其他实体瘤获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674814449","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674814449?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 16:22","pubTimestamp":1791706938,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》，公司自主研发的全球首创、新概念、全球首个且唯一获批上市的EGFR×HER3双抗ADC宜泽康联合用药的临床试验获得批准。截至目前，宜泽康已在中国和美国开展了超45项针对多种肿瘤类型的临床试验，其中，III期临床研究20项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91194","PSYK","BMED","688506","IBBQ","MDTX","IBBJ","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674141158","title":"精华制药：季德胜蛇药片2026年获批带状疱疹临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2674141158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674141158?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 16:13","pubTimestamp":1791706382,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","IBBJ","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674814165","title":"我武生物：获得干细胞注射液药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674814165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674814165?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 16:09","pubTimestamp":1791706178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","IBBJ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674814516","title":"百利天恒：宜泽康联合放疗临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2674814516","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674814516?lang=zh_cn&edition=fundamental","pubTime":"2026-10-11 15:47","pubTimestamp":1791704832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","IBBQ","MDTX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674899603","title":"清华证研院：创新药板块景气修复与医疗器械自主可控构成9月主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2674899603","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674899603?lang=zh_cn&edition=fundamental","pubTime":"2026-10-10 15:28","pubTimestamp":1791617326,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯（记者张玮华）清华大学全球证券市场研究院（以下简称“清华证研院”）发布《中国上市公司市值分析月度报告（2026年9月）》。清华证研院院长助理、中国上市公司市值管理研究负责人迟永胜接受上证报记者采访时表示，9月A股市场整体呈现调整回落、估值同步压缩的运行态势；行业方面，房地产、医药生物、银行等板块逆势上涨，价值防御风格占优特征清晰。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11215,202610103891917365.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11215,202610103891917365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["MEDX","BK1161","BK1583","PTH","159992","IBBQ","IEIH","BK1100","RSPH","AGNG","BK1574","HART","MDEV","LGHT","09996","LNGR","06978","159883","GDOC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}